Baxalta Inc (BXLT) Acquisition by Shire May Happen As Soon As Monday


Shares of Baxalta Inc (NYSE:BXLT) have suddenly jumped into the green as rumors are spreading that a possible $32.5 billion Shire Acquisition of the company may take place as soon as Monday. With just one trading day left, investors seem to be betting on such a deal, which is said to be part cash, part stock. The deal, which would likely value Baxalta Inc (NYSE:BXLT) at $48 per share, would equate to approximately a 20% premium over the current share price.

Shire had first offered Baxalta shareholders $45 per share back in July, but that deal never took place. At the end of December Reuters had stated that Shire had made a new offer which met Baxalta’s valuation expectation. If the deal does go through it would be the largest healthcare acquistion in this young year so far.

The stock is currently trading higher by 3.49% or $1.37 following the positive news, hitting $40.67 per share at the time of us publishing this article. About 4.47M shares traded hands or up 0.68% from the average. BXLT has risen 6.00% since December 8, 2015 and is currently uptrending. It has outperformed the S&P500 by 10.69%.

From a total of 4 analysts covering Baxalta Incorporated (NASDAQ:BXLT) stock, 3 rate it a “Buy”, 0 a “Sell”, and 1 a “Hold”. This means that 75% of the ratings are positive. The highest target price is $42 while the lowest target price is $38. The mean of all analyst targets is $40.67 which is 0.00% above today’s ($40.67) stock price. Baxalta Incorporated was the topic of 4 analyst reports since August 11, 2015 according to the firm StockzIntelligence Inc. William Blair initiated shares on August 18 with a “Outperform” rating.

Baxalta Incorporated is a biopharmaceutical company. The company has a market cap of $28.07 billion. The Firm develops, makes and markets a portfolio of treatments for hemophilia and other bleeding disorders, immune deficiencies, alpha-1 antitrypsin deficiency, burns and shock, and other chronic and acute medical conditions. It has 23.79 P/E ratio. The Firm also focuses on disease areas, including oncology, as well as technology platforms, including gene therapy and biosimilars.